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Abstract
Oxidative events – the oxidation of low-density lipoproteins (LDL) in the first 
place – have been shown to participate in the progression of atherosclerosis and precipita-
tion of cardiovascular events. This occurs through modulation of important compo-
nents of lesions of the vessel wall (smooth muscle cell proliferation, protease/anti-
protease balance, endothelial functions). Our recent studies have provided evidence 
that the enzyme gamma-glutamyltransferase (GGT), normally found in serum, is often 
accumulated within the plaque environment in substantial amounts, and that this acti-
vity is a potential source of a variety of prooxidant species. Concurrently, epidemio-
logical research has conclusively documented that the serum levels of GGT are an 
independent factor in prognosis of myocardial infarction and stroke in atheroscle-
rotic patients. Several signs suggest that the GGT appearing in plaque tissue may 
originate from the serum enzyme, which in facts associates with the circulating lipo-
protein fractions. Thus, data seem to point out that pathogenesis of atherosclerosis 
and in particular of the events leading to progression of the disease and acute cardio-
vascular events – might include an as yet unexplored pathway, based on the prooxidant 
effects of gamma-glutamyltransferase accumulating as a result of LDL entry in the 
vessel wall. 
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Introduction 
Understanding factors participating in the 
progression of atherosclerotic lesions would 
allow the identification of high-risk lesions, in 
which the pathological changes produced by the 
disease process are more likely to result in plaque 
rupture, thrombosis and the associated ischemic/
necrotic sequelae. Establishing timely treatment 
for such lesions would clearly represent a major 
advance in secondary prevention and therapy of 
cardiovascular patients. 
Oxidative reactions occupy an important 
position among factors of plaque progression and 
“destabilization” [Stocker R., Keaney J.F. Jr., 2004]. 
One specific oxidative event – the oxidation of 
low density lipoprotein (LDL) – had been high-
lighted by earlier studies as the single crucial 
event in pathogenesis of atherosclerosis, with 
special reference to the initiation of lesions. Sub-
sequent research has shown however that the 
implication of oxidative processes may be con-
siderably wider, extending to include effects on 
several other important pathological changes 
occurring in the diseased vessel wall. Thus, it has 
been shown that oxidants and redox reactions 
are involved in stimulation of smooth muscle 
cell proliferation, contributing to lesion thick-
ness and expansion. The activities of matrix 
metalloproteinases and of their inhibitors – major 
determinants of plaque stability – are modulated 
through redox changes in critical portions of 
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their protein structure. Some aspects of endothelial 
dysfunction [e.g. impairment of nitric oxide (NO) 
production, expression patterns, and levels of 
adhesion molecules] are also affected by oxida-
tive events, and several other redox-sensitive steps 
are present in signal transduction, apoptotic cell 
death and platelet functions. Current experimental 
studies consistently indicate that oxidation/
reduction processes may be frequently involved 
in the production of changes capable of turning 
a mildly stenotic, silent plaque into a vulnerable, 
symptomatic, and potentially fatal lesion. A series 
of enzyme activities expressed by cellular elements 
present in the lesions (endothelium, phagocytes, 
smooth muscle cells, fibroblasts) have been pro-
posed as sources of the oxidants involved; these 
include NADPH-oxidases, NO-synthase, xantine 
oxidase, myeloperoxidase, lipoxygenases and 
enzymes of mitochondrial respiration. Non-enzy-
mic prooxidants also participate in the reactions, 
such as transition metals (iron, copper) and lipid 
peroxides. However, the relative roles and impor-
tance of each of the mentioned factors in the 
“oxidative progression” of lesions have not been 
elucidated yet, and are likely to depend on which 
aspect of the process is being considered; the 
whole matter is in fact the subject for extensive 
experimental research. 
Involvement of gamma-glutamyltransferase 
(GGT) activity in atherosclerosis. Serum GGT 
levels are best known as a reliable index of 
hepatobiliary dysfunction and alcohol abuse 
[Whitfield J.B., 2001], but recent studies have 
repeatedly proposed an independent role of GGT 
in clinical evolution of cardiovascular diseases 
related with atherosclerosis [Pompella A. et al., 
2004]. Several studies had documented that 
serum GGT is associated with overall mortality 
and cardiovascular events in both unselected popu-
lations [Conigrave K.M. et al., 1993; Wanna-
methee G. et al., 1995; Brenner H. et al., 1997; 
Jousilahti P. et al., 2000] and patients with ascer-
tained coronary artery disease, independent of all 
confounders including liver function and alcohol 
consumption [Karlson B.W. et al., 2000]. A recent 
prospective study carried out in as many as 
163,944 adult subjects [Ruttmann E. et al., 2005] 
has now rather conclusively shown that serum 
GGT levels are an independent prognostic factor 
for fatal events of chronic forms of coronary artery 
disease, congestive heart failure and ischemic or 
hemorrhagic stroke. The finding was true for 
both sexes, with a clear dose-response relation-
ship and a stronger significance as far as younger 
subjects were concerned. 
The prognostic value of serum GGT activity 
for cardiac death and non-fatal infarction had 
been previously documented in our prospective 
study, including a six-year follow-up of 469 
patients with ischemic syndrome and angio-
graphically documented coronary artery disease 
[Emdin M. et al., 2001]. In this study, the signifi-
cance of serum GGT was more evident in a 
subset of patients prone to plaque complications, 
i.e. characterized by the association of diffuse 
atherosclerosis (multivessel disease) and a history 
of previous myocardial infarction (approx. 36% 
of the whole population). The risk was increas-
ing using two different GGT cut-off values (25 
or 40 U/l, both generally considered within the 
normal range), the event excess being concen-
trated within the first three-year period. The 
prognostic significance of serum GGT was thus 
correlated with the diffusion of coronary artery 
disease, and interestingly, the significance of 
serum GGT appeared to depend on the insta-
bility of plaques, as indicated by the fact that the 
prognostic value of GGT disappeared after 
revascularization by angioplasty, a procedure 
thought to effect plaque stabilization. The unfa-
vourable prognosis signaled by elevated serum 
GGT appeared thus to apply specifically to 
patients with vulnerable plaques, suggesting that 
connections of some kind may exist between GGT 
and the processes involved in plaque stability 
[Emdin M. et al., 2001]. 
Importantly, all of the studies mentioned 
above refer to “normal” serum GGT, i.e. values 
within the laboratory reference range, such as in the 
large prospective study by Wannamethee et al. 
(7613 middle-aged men, with a 11-years follow-up), 
showing that GGT levels in the normal range 
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(top quintile of distribution) were strongly asso-
ciated with a significant increase in deaths from 
ischemic heart disease [Wannamethee G. et al., 
1995]. Serum GGT was positively correlated 
with preexisting ischemic heart disease (IHD), 
diabetes mellitus, antihypertensive medication, 
systolic and diastolic blood pressure, total and 
high-density lipoprotein (HDL) cholesterol, 
heart rate and blood glucose. After adjustment for 
these variables, elevated GGT (highest quintile, 
≥ 24 U/l, vs. the rest) was still associated with a 
significant increase in mortality from all causes 
and from IHD. The increased risk of IHD mor-
tality was more marked for patients with evidence 
of IHD at screening, particularly those with pre-
vious myocardial infarction [Wannamethee G. 
et al., 1995]. The increased mortality in men 
without heart disease was obviously dependent on 
other causes; on the other hand, the findings in 
ischemic patients again pointed to a connection of 
serum GGT with unknown aspects of the under-
lying atherosclerotic coronary artery disease. 
An indirect confirmation for the implication 
of circulating GGT in the evolution of athero-
sclerosis derives from evidence obtained by his-
tochemistry. Histochemical studies performed in 
our laboratories showed that intense GGT activity 
is often present in the intimal layers of human 
atherosclerotic lesions, where it is apparently 
expressed in CD68+ macrophage-derived foam 
cells [Paolicchi A. et al., 1999; Paolicchi A. et al., 
2004]. GGT-positive foam cells were found to 
co-localize with immunoreactive oxidized LDL 
[Emdin M. et al., 2002], and catalytically active 
GGT could be also detected in microthrombi 
adhering to the surface of atheromas [Dominici S. 
et al., 2003]. Whether GGT activity found in 
plaque tissue is actually participating in the dis-
ease – or is rather an epiphenomenon lacking 
specific significance – remains to be ascertained. 
At least two questions arise: i) how could GGT 
activity affect the progression of the disease, and 
ii) how are serum levels of GGT related with the 
enzyme detectable in plaques? 
Functions of gamma-glutamyltransferase – 
unexplored aspects. GGT enzyme activity has 
complex biochemical functions, and its overall 
physiological significance has not been entirely 
appreciated yet. Several aspects of GGT activity 
are indeed capable to promote effects of oxidative 
nature, which in principle might contribute to 
progression of the atherosclerotic process. Most 
of the knowledge about GGT functions is con-
cerned with the roles played by this activity at 
the cellular level. High GGT levels are expressed 
in kidney tubules, biliary epithelium, and brain 
capillaries; however, lower or trace levels are 
detectable in many more cell types, e.g. blood 
cells, endothelium, and notably secretory and 
absorptive cells [Hanigan M.H., Frierson H.F. Jr., 
1996]. Being located at the plasma membrane 
level, GGT catalyzes the first step in the degra-
dation of extracellular glutathione (GSH), i.e. 
the hydrolysis of the gamma-glutamyl bond 
between glutamate and cysteine. In this process, 
GGT releases the dipeptide cysteinyl-glycine, 
which is subsequently cleaved to cysteine and 
glycine by plasma membrane dipeptidase activi-
ties.Thus, GGT activity provides cells first of all 
with a means for the recovery of precursors 
needed to reconstitute the intracellular levels of 
glutathione, the main cellular antioxidant (Fig-
ure 1A). Novel insights however have been 
prompted by studies showing the ability of GGT 
to play a prooxidant role under selected condi-
tions. The key issue in this alternative function 
of GGT is related to the reducing properties of 
GSH and the thiol metabolites originating from 
GGT activity. Thiols – especially when dissoci-
ated to their thiolate anion forms (R-S–) – can 
effect the reduction of metal cations, e.g. iron 
and copper. Electrons can then be transferred in 
turn from metal ions to molecular oxygen, thus 
generating the reactive oxygen species superoxide 
anion and hydrogen peroxide, both capable of 
stimulating prooxidant reactions. The sequence 
– a true “redox cycling” of metals [Kappus H., 
Sies H., 1981] – can proceed with even minimal 
concentrations of metal ions as long as the electron 
donors (thiols) and electron acceptor (molecular 
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oxygen) are available. In this way, and paradoxi-
cally, the ‘reducing’ abilities of thiols are even-
tually turned into overall ‘oxidizing’ effects. 
Stark et al. [Stark A.-A. et al., 1993] were the 
first to propose that the catabolism of GSH can 
play a prooxidant role under selected conditions. 
These authors suggested that the GGT-mediated 
cleavage of GSH – allegedly through the genera-
tion of the more reactive thiol cysteinyl-glycine 
– could cause the reduction of ferric iron Fe(III) 
to ferrous iron Fe(II), thus starting an iron-
dependent redox-cycling process liable to result 
in the production of reactive oxygen species 
(ROS) and the stimulation of oxidative reactions 
(Figure 1B). Subsequent studies from our and 
other laboratories have repeatedly documented 
the production of ROS during the catabolism of 
GSH mediated by cellular GGT. The biochemi-
cal processes involved have been characterized 
(reviewed in [Dominici S. et al., 2003], and some 
of the redox effects occurring at the cellular level 
have been described, e.g. on the activation status 
of transcription factors and apoptotic signalling 
pathways [Del Bello B. et al., 1999; Paolicchi A. 
et al., 2002; Dominici S. et al., 2003]. 
The observation of such prooxidant reactions 
has refined our understanding of GGT functions, 
the significance of which appears to be dual. At 
a cellular level, it is conceivable that the prooxi-
Figure 1. Functions of gamma-glutamyltransferase (GGT) activity: (GSH), glutathione; (Cys-Gly), cysteinyl-glycine. 
(A) cellular supply of precursors for the resynthesis of intra-
cellular stores of the antioxidant glutathione. 
(B) promotion of metal-catalyzed redox reactions, leading to 
the appearance of reactive oxygen species, free radicals and 
oxidative modifications on proteins. 
dant effects of plasma membrane GGT are 
normally balanced by its established role in 
favouring the cellular uptake of precursors for 
GSH resynthesis, thus allowing the maintenance 
of cellular antioxidant defenses. On the other 
hand, the functions of soluble GGT activity in 
serum are less directly related to the cellular 
supply of GSH, and conditions likely exist in 
which its prooxidant effects may be prevailing. 
The free iron required for such processes can 
originate from iron storage proteins; it was in fact 
shown that GGT prooxidant effects are sustained 
by both transferrin and ferritin [Dominici S. et al., 
2003; Corti A. et al., 2005]. The emerging pro-
oxidant potential of serum GGT can help explain 
the recent observation that baseline serum GGT 
can predict future elevations of serum F2-iso-
prostanes, a sensitive marker of oxidative stress 
[Lee D.H. et al., 2003; Lee D.H. et al., 2004]. 
As far as the plaque environment, free iron is 
present [Pang J.H. et al., 1996] at levels suffi-
cient to sustain the GGT-mediated prooxidant 
effects [Paolicchi A. et al., 1999]. 
Serum GGT vs. enzyme activity present in 
atherosclerotic plaques. The liver being the 
apparent main source for circulating GGT activity 
[Stocker R., Keaney J.F. Jr., 2004], constitutive 
high serum levels have been reported in families 
as an inherited autosomic dominant character, and 
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in the apparent absence of any disease (see e.g. 
[Bibas M. et al., 1994]. Genetic effects could in 
principle involve either the release of GGT from 
liver cells or its clearance from circulation. Other 
liver enzymes partly share the same effects, and 
this seems to indicate that genetic factors may be 
operative at the level of GGT release in blood 
[Whitfield J.B. et al., 2002]. The importance of 
genetic factors is still a matter for discussion. 
The current view is that a mixture of genetic and 
environmental factors can influence serum GGT 
[Bathum L. et al., 2001; Whitfield J.B. et al., 2002]. 
Another line of evidence points to the possibility 
that the source of serum GGT may be identified 
in circulating platelets, as the two parameters are 
usually correlated [Bolodeoku J.A. et al., 1997]. 
Thus, it has been proposed that the increased GGT 
levels observed in atherosclerotic patients may 
originate from increased platelet consumption at 
the site of plaques [Krijgsman B. et al., 2003]. 
It has long been appreciated that serum 
GGT is partially adsorbed onto circulating LDL 
[Huseby N.E., 1982; Watanabe M. et al., 1984]. 
Details of such association were recently inves-
tigated by us in a population of patients with 
angiographically documented coronary artery dis-
ease (CAD) [Paolicchi A. et al., 2006]. As GGT 
activity in non-cholestatic patients is mainly 
associated with HDL and LDL [Watanabe M. 
et al., 1984], the amount of GGT activity associ-
ated with polycation-precipitated beta-lipopro-
teins (beta-LP) – which include LDL, intermediate 
density lipoprotein (IDL) and very low density 
lipoprotein (VLDL), but not HDL – was assumed 
as an index of LDL-associated GGT. It was thus 
observed that both in controls and in CAD 
patients the amount of GGT associated with 
beta-LP is directly proportional to total serum 
GGT levels; in CAD patients however, the beta-
LP-associated fraction was significantly lower. 
Furthermore, serum GGT is known to increase 
with age, and such increase was indeed found in 
the control group. In contrast, significantly lower 
total serum GGT levels were detected in older 
CAD patients, though the ratio between beta-
LP-bound and total GGT remained constant 
[Paolicchi A. et al., 2006]. It remains to be 
elucidated whether this phenomenon depends on 
the absence in CAD patients of the factor(s) elic-
iting the increase of serum GGT with age, or 
rather to a selective loss of patients with higher 
GGT [Emdin M. et al., 2001], due to (GGT-related?) 
complications of CAD, i.e. cardiac death and 
stroke. The reasons for the association of GGT 
with LDL likely lie in the peculiar structure of 
GGT, a dimeric protein the heavy chain of which 
contains a lipophilic domain responsible for the 
plasma membrane insertion of the cellular enzyme. 
Several proteases are capable of digesting the 
lipophilic domain, thus producing a hydrophilic 
form of the protein [Meister A., 1983]. The specific 
association of GGT with LDL and the nature of 
the protein were further confirmed by ultracen-
trifugation. We found that the LDL-associated 
enzyme consists in an entire heavy chain, indi-
cating that the amphiphilic form of the enzyme 
is involved [Paolicchi A. et al., 2006]. It is known 
however that the incubation of amphiphilic GGT 
with isolated lipoprotein does not produce GGT-
lipoprotein complexes [Artur Y. et al., 1984], 
suggesting that the interaction of GGT with lipo-
protein may be different from the one with plasma 
membrane lipids. Indeed, affinity-adsorbed LDL 
released most of its GGT activity following 
extensive washing, indicating a rather labile 
LDL/GGT association [Paolicchi A. et al., 2006]. 
The beta-LP-associated fraction of GGT is 
proportional to total serum GGT; thus, binding 
of GGT with LDL might itself be related to the 
reported increase of cardiovascular risk. What 
mechanisms could then account for the observed 
decrease of beta-LP-bound GGT in CAD patients 
and the decrease of total GGT levels in older ones? 
Conceivably, the reasons might be (i) a less effi-
cient association of GGT with LDL in these 
patients, (ii) an enhanced release of GGT from 
LDL, or (iii) an enhanced uptake of LDL–GGT 
complexes within atherosclerotic lesions, possi-
bly of those presenting with higher GGT con-
tents. The latter hypothesis is particularly attrac-
tive, as it would allow the integration of an 
overall picture with the histochemical findings 
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(Figure 2): the enhanced uptake of LDL–GGT 
complexes, leading to the appearance of signifi-
cant deposits of active GGT within the lesions, 
might be a discrete step in atherogenesis, poten-
tially explaining the reported correlation between 
higher levels of serum GGT and the clinical con-
sequences of atherosclerosis. 
Conclusions 
Current studies in our laboratory are aimed to 
a further biochemical characterization of GGT 
present in human atherosclerotic plaques. As a 
confirmation of the hypothesis discussed above, 
preliminary data indicate that the enzyme pro-
tein accumulating in lesions has molecular 
weight and chromatographic properties compat-
ible with those of serum GGT. In addition, pro-
teins recovered form plaque tissue present with 
some degree of S-cysteyl-glycylation, i.e. the 
form of protein S-thiolation specifically cata-
lysed by GGT [Corti A. et al., 2005], thus wit-
nessing the occurrence of prooxidant reactions 
promoted by the accumulated enzyme [Franzini 
M. et al., 2008]. It seems therefore reasonable to 
speculate that the prooxidant reactions promoted 
by GGT activity might contribute to the (oxida-
tive) processes involved in several aspects of 
plaque destabilization. Further studies are nec-
essary however in order to identify the factors 
that favour the uptake of GGT within plaques, 
and possibly accelerate it in selected subjects. 
Figure. 2. Possible relationships between GGT activity 
circulating in serum in association with distinct lipoprotein 
fractions, and GGT activity detectable in atherosclerotic le-
sions. Available data suggest that the latter might result from 
the uptake of  GGT/LDL complexes within the arterial wall. 
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